Abstract
Health issueCervical cancer is one of the most common malignant diseases of women; it is diagnosed in almost half a million women every year and half as many die from it annually. In Canada and other industrialized countries, its incidence has decreased due to cytology screening. However, invasive cases still occur, particularly among immigrant groups and native Canadian women. Although incidence of squamous cell carcinomas has decreased, the proportion of adenocarcinomas has increased because Pap cytology is ineffective to detect these lesions.Key findingsIn Canada, cervical cancer will cause an estimated 11,000 person-years of life lost. In most Canadian provinces, early detection is dependent on opportunistic screening. Primary prevention can be achieved through health education (sexual behavior modification) and vaccination to prevent infection from Human Papillomavirus (HPV). The initial results from vaccination trials are encouraging but wide scale use is more than a decade away.Data gaps and recommendationsMost cases of cervical cancer occur because the Pap smear was either false negative, was not done or not done often enough. Appropriate recommendations and guidelines exist on implementation of cytology-based programs. However, most Canadian women do not have access to organized screening. Further research is needed to 1) evaluate automated cytology systems; 2) define appropriate management of precursor lesions and 3) deliver definitive evidence of HPV testing efficacy in long-term follow-up studies with invasive cancer as an outcome and 4) provide Canadian data to justify augmenting or modifying current programs to use HPV testing in secondary triage of equivocal Pap smears.
Highlights
Cervical cancer is a malignant neoplastic disease that tends to begin slowly when there is a disruption of the cervical epithelium, near the squamocolumnar junction of the uterine cervix
This pre-invasive process is limited to the cervical epithelium and is known variably as cervical intraepithelial neoplasia (CIN), according to the classification scheme mostly used in histopathology, or as squamous intraepithelial lesion (SIL), as per the classification system favoured for cytopathological diagnosis
Low-grade SIL (LSIL) may become HSIL, and the latter may eventually extend to the full thickness of the cervical epithelium, a condition that is recognized as cervical carcinoma in situ (CIS)
Summary
Cervical cancer is a malignant neoplastic disease that tends to begin slowly when there is a disruption of the cervical epithelium, near the squamocolumnar junction of the uterine cervix. This pre-invasive process is limited to the cervical epithelium and is known variably as cervical intraepithelial neoplasia (CIN), according to the classification scheme mostly used in histopathology, or as squamous intraepithelial lesion (SIL), as per the classification system favoured for cytopathological diagnosis. Low-grade SIL (LSIL) (equivalent to CIN 1) and highgrade SIL (HSIL, equivalent to CIN 2 and 3) are invariably asymptomatic and can be detected through cytological examination using the Papanicolaou technique (the Pap test). As soon as lymph node metastasis occurs the disease worsens considerably
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have